BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion

Table 4 Correlation between the level of BCL-2 in T cells and clinical characteristics of patients with CLL

characteristics		BCL-2 positive percentage		χ²	P
		< 20%	≥20%	χ²	P
Sex	Male	27	140	1.516	0.218
	Female	22	77
Age(years)	≤65	33	142	0.065	0.799
	> 65	16	75
Binet stage	Stage A	14	55	0.263	0.877
	Stage B	18	80
	Stage C	17	82
β2-MG	≤3.5 mg/L	22	131	3.916	0.048
	> 3.5 mg/L	27	86
IGHV	Mutated	28	122	0.014	0.906
	Unmutated	21	95
TP53 disruption	Yes	10	29	1.585	0.208
	No	39	188
Del(13q)	Yes	16	73	0.018	0.895
	No	33	144
Del(11q)	Yes	7	29	0.029	0.865
	No	42	188
CLL-IPI risk	low	12	56	0.238	0.971
	medium	15	65
	high	15	70
	very high	7	26

The tests used in Table 4 were all Chi-Square test or Fisher’s exact test
Abbreviations: β2-MG β2-microglobulin, IGHV immunoglobulin heavy variable-region gene, TP53 tumor protein 53, Del delete, IPI International Prognostic Index

ISSN: 1476-4598